SAC StudioThe high-strength, heavy-metal-tested bulk refill for committed users.
Double Wood Boswellia answers a specific question: I've confirmed boswellia helps my joints — what's the best long-haul bulk supply? It's a genuinely high-strength extract (1,000 mg per capsule at 65% boswellic acids, roughly 650 mg of acids per cap) in a 240-capsule mega-bottle, at one of the lowest costs-per-cap on the list. The standout is testing: Double Wood explicitly third-party tests for heavy metals and potency and publishes batch COAs — a meaningful safeguard for a resin extract.
The trade-offs are the familiar ones: it standardises to total boswellic acids rather than a stated AKBA %, it carries no co-factors, and the big bottle is poor value if boswellia turns out not to help you. This rounds out the list as the committed-user refill, not the first bottle. Here's the full breakdown.
A high standardisation figure — 65% boswellic acids, roughly 650 mg of acids per 1,000 mg cap — well above the unstandardised resin that fills the budget aisle. It sits in the strong mid tier, trailing the 5-Loxin / AprèsFlex picks only because it standardises to total boswellic acids rather than a stated AKBA %, the same precision gap as NOW and Nutricost.
At 1,000 mg per cap, one capsule is a strong single-serving dose and two caps land comfortably in the ~1,000 mg/day-plus window (Kimmatkar 2003). The high per-cap strength makes reaching the trial dose easy; the score is held just below the top because the trial split its dose three times daily, where a single 1,000 mg cap delivers it in one hit.
A genuine strength: Double Wood explicitly third-party tests for heavy metals and potency and publishes batch COAs, made in the USA. For a resin extract — where heavy-metal contamination is a real risk — that explicit testing is a relevant, above-average safeguard for the price tier, even if the brand isn't positioned as clinician-grade.
One of the lowest costs-per-cap on the list — roughly $20 for 240 caps, about $0.08 per 1,000 mg cap. The bulk format drives strong cost-per-serving once you're committed to daily use, though the large bottle is poor value if boswellia turns out not to help you, so it's a refill rather than a first buy.
A clean single-active standardised extract — no proprietary blend, no junk fillers hiding the dose. It scores solidly but not top, because it adds nothing beyond the extract (no turmeric co-factor like NOW, no hypoallergenic standard like Pure Encapsulations) — the deliberate trade for a high-strength, low-cost-per-cap bulk bottle.
“Standardised to 65% boswellic acids, 1,000 mg per capsule.”
A genuine, high standardisation figure consistent with Double Wood's published label — roughly 650 mg of boswellic acids per 1,000 mg cap. This is a real, high-strength active spec, not the unstandardised resin that fills the rest of the budget aisle.
“Third-party tested for heavy metals and potency.”
Double Wood explicitly third-party tests its products and publishes batch certificates of analysis — for a resin extract, heavy-metal verification is a relevant and meaningful safeguard. This testing transparency is one of the product's genuine differentiators and above average for the price tier.
“Supports joint health and a normal inflammatory response.”
Boswellia's joint and anti-inflammatory benefits are backed by real RCTs — Kimmatkar 2003 (PMID 12622457) found a standardised extract reduced knee-OA pain and improved function versus placebo over 8 weeks. A 65%-standardised extract at 1,000-2,000 mg/day sits within that evidence base.
“Premium high-potency boswellia.”
High-potency, yes; premium, partly. The 1,000 mg per cap at 65% is genuinely high-strength and the heavy-metal testing is real quality — but Double Wood is a value brand, not a clinician-grade marque, and it standardises to total boswellic acids rather than a named AKBA fraction. Strong potency and testing; "premium" overstates the brand tier.
Double Wood's case rests on three things working together: a genuinely high-strength dose (1,000 mg per cap at 65% boswellic acids), explicit third-party heavy-metal testing, and a 240-cap bulk bottle at one of the lowest costs-per-cap on the list. The heavy-metal testing is the standout — boswellia is a resin extract, and resins can carry contamination, so independent verification is a real safeguard rather than marketing. For a committed user taking boswellia daily for months, a tested, high-strength bulk supply is exactly the right package.
At 1,000 mg per capsule, one cap is a strong standardised dose and two land comfortably in the trial window — easier dosing than the lower-strength whole extracts that need three caps. At one to two caps daily, the 240-cap bottle lasts four to eight months, the longest runway on the list. That bulk format is the whole appeal, but it's also why this isn't a first purchase: a multi-month supply is too much to commit before you know you respond. Test with a smaller bottle first, then buy this as the refill.
Like NOW (#1), Nutricost (#6), and the other whole-extract picks, Double Wood standardises to total boswellic acids (65%) rather than a stated AKBA percentage — so it trails the pure-play AKBA picks (Life Extension 5-LOXIN #2) on the most potent fraction. The standardisation is high and real, and the heavy-metal testing is a genuine plus; the precision gap is the familiar trade-off of a whole-extract product. If matching the AKBA-enriched evidence exactly is your priority, 5-LOXIN is the pick.
Double Wood has built its reputation on third-party testing and publishing batch COAs, and on this product that means explicit heavy-metal and potency verification, made in the USA. It isn't a clinician-grade marque, but its testing transparency is above average for the value tier — and crucially, the kind of testing it does (heavy metals on a resin extract) is exactly the kind that matters for this botanical. That's a more relevant quality signal here than it would be for a simple single-molecule supplement.
Position Double Wood correctly and it's a strong buy: it rounds out the list as the high-strength, heavy-metal-tested, lowest-cost-per-cap bulk supply for someone who already knows boswellia works for them. It's not the bottle to discover boswellia with (too much commitment), the AKBA-precision pick (that's 5-LOXIN #2), or the co-factor pick (NOW #1) — and it shouldn't be bought expecting those. Buy it as the long-haul refill once a smaller pack has proven the supplement helps your joints.
Double Wood Boswellia is the sensible bulk-buy once you've confirmed boswellia helps your joints — a genuinely high-strength extract (1,000 mg at 65% boswellic acids) in a 240-cap mega-bottle at one of the lowest costs-per-cap on the list, and notably third-party tested for heavy metals, which matters for a resin extract. You give up AKBA precision (it standardises to total boswellic acids, like NOW) and co-factors, but you keep a tested, high-strength, long-runway supply at an excellent cost-per-cap. It rounds out the list rather than leading it, and the sequencing matters: don't make it your first bottle. Test boswellia with a smaller, cheaper pack first — Swanson (#5) or Nutricost (#6) — and once you know you respond, switch to Double Wood as the long-haul refill. Choose differently from the start if your priority is AKBA precision (Life Extension 5-LOXIN #2), a complementary co-factor (NOW #1), or a clinician-grade clean label (Pure Encapsulations #4). For a committed user who wants a high-strength, heavy-metal-tested bulk supply, Double Wood is the right answer — one to two caps a day with food.
Affiliate link — Super Achiever Club earns a small commission at no extra cost to you.
A 65%-standardised extract delivering 1,200 mg per two-cap serving at the lowest cost-per-gram on the list, in a 180-cap bottle. The smaller-bottle value pick to test boswellia before committing to the 240-cap Double Wood.
See it on the list →The named AKBA-enriched 5-Loxin extract (~30% AKBA) the strongest trial used. The upgrade if you want maximal AKBA precision rather than a high-strength bulk supply.
See it on the list →The cheapest standardised boswellia on the list in a smaller 100-cap bottle — the low-risk way to test whether boswellia works for you before buying the 240-cap Double Wood refill.
See it on the list →Randomised, double-blind, placebo-controlled crossover trial in knee-osteoarthritis patients: a standardised Boswellia serrata extract significantly reduced knee pain, improved function, and increased walking distance versus placebo over 8 weeks. The efficacy and dosing basis (~333 mg three times daily, ~1,000 mg/day) for a standardised extract like Double Wood's.
Placebo-controlled trial of 5-Loxin (an AKBA-enriched Boswellia extract, ~30% AKBA) at 100 and 250 mg/day in knee osteoarthritis: significant, dose-related pain and function improvements, with benefits within ~7 days at 250 mg. Defines the AKBA-enriched precision tier Double Wood's total-boswellic-acid standardisation sits below.
